XERS
Xeris Biopharma Holdings, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+79/100
Last price
9.95
▼ 0.18 (1.78%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
9.95
Prev close
10.13
Day high
10.32
Day low
9.90
Volume
2.40M
Market cap
$1.84B
P/E (TTM)
—
52W range
5.25 – 11.33
Day trading desk
Gap from prior close
-1.78%
Prior close 10.13
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
9.95 – 9.95
Position in range
—
—
ATR (14D)
0.64
6.48% of price
Prior day high
10.24
PDH
Prior day low
9.12
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 2.19M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.90%
-1.0%
1M
+18.05%
+16.9%
3M
+16.15%
+11.6%
6M
+71.55%
+53.4%
YTD
+28.28%
+14.0%
1Y
+22.80%
+6.4%
3Y
+441.40%
+359.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on XERS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-163.62K
Net selling
Buy transactions
6
154.55K shares
Sell transactions
14
318.17K shares
Net transactions
+20
Buys less sells
Sell : buy shares
2.1 : 1
Mixed
Insider-held shares
5.52M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 28, 26 | MCCULLOCH KEVIN President |
SELL | 25.00K | $250.00K | Direct |
| Sep 1, 26 | HECHT BETH P Officer |
SELL | 16.67K | $141.43K | Direct |
| Sep 1, 26 | PIEPER STEVEN Chief Financial Officer |
SELL | 5.00K | $42.50K | Direct |
| Sep 1, 26 | MCCULLOCH KEVIN President |
SELL | 15.00K | $127.31K | Direct |
| Aug 12, 26 | PIEPER STEVEN Chief Financial Officer |
SELL | 5.00K | $42.50K | Direct |
| Aug 3, 26 | HECHT BETH P Officer |
SELL | 16.67K | $133.55K | Direct |
| Aug 3, 26 | MCCULLOCH KEVIN President |
SELL | 15.00K | $120.24K | Direct |
| Jul 7, 26 | PIEPER STEVEN Chief Financial Officer |
SELL | 45.00K | $383.18K | Direct |
| Jul 1, 26 | HECHT BETH P Officer |
SELL | 16.67K | $133.86K | Direct |
| Jul 1, 26 | MCCULLOCH KEVIN President |
SELL | 90.00K | $722.51K | Direct |
| Jul 1, 26 | KREHER NERISSA C Director |
STOCK | 33.58K | $0 | Direct |
| Jun 4, 26 | BORMANN-KENNEDY BARBARA-JEAN ANNE Director |
SELL | 16.00K | $97.51K | Direct |
| Jun 4, 26 | HALKUFF DAWN Director |
SELL | 20.00K | $121.89K | Direct |
| Jun 4, 26 | BORMANN-KENNEDY BARBARA-JEAN ANNE Director |
STOCK | 24.19K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BORMANN-KENNEDY BARBARA-JEAN ANNE |
Director | 150.69K | Sale |
HECHT BETH P |
Officer | 1.13M | Sale |
JOHNSON JOHN H. |
Director | 698.08K | Sale |
KONG GARHENG |
Director | 238.34K | Stock Award(Grant) |
MCCULLOCH KEVIN |
President | 1.64M | Sale |
NGUYEN ANH TU |
Officer | 431.53K | Stock Award(Grant) |
PERSKY MARLA S |
Director | 157.06K | Stock Award(Grant) |
PIEPER STEVEN |
Chief Financial Officer | 1.36M | Sale |
SHANNON JOHN PATRICK JR |
Chief Executive Officer | 2.94M | Stock Award(Grant) |
SHERMAN JEFFREY W |
Director | 224.59K | Sale |
Fundamentals
Market cap$1.84B
Enterprise value$2.00B
Revenue (TTM)$335.41M
Gross profit$290.38M
EBITDA$48.77M
Net income$-17.16M
EPS (TTM)$-0.10
Free cash flow$52.45M
Total cash$121.75M
Total debt$289.44M
Book value / share$-0.06
Shares outstanding182.32M
Float176.07M
Short % of float4.57%
Dividend yield0.00%
Beta (5Y)0.84
Valuation & profitability ratios
Trailing P/E—
Forward P/E27.22
PEG ratio—
Price / sales—
Price / book—
EV / revenue5.97
EV / EBITDA41.09
Gross margin86.57%
Operating margin5.62%
Profit margin-5.12%
Return on equity—
Return on assets6.13%
Debt / equity—
Current ratio1.45
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $291.85M | $203.07M | $163.91M | $110.25M | +43.7% |
| Operating revenue | $291.85M | $203.07M | $163.91M | $110.25M | +43.7% |
| Cost of revenue | $42.57M | $36.83M | $28.64M | $22.63M | +15.6% |
| Gross profit | $249.28M | $166.24M | $135.27M | $87.61M | +50.0% |
| Research & development | $31.16M | $25.56M | $22.34M | $20.97M | +21.9% |
| Selling, general & admin | $182.37M | $163.48M | $146.09M | $137.75M | +11.6% |
| Total operating expense | $224.38M | $199.88M | $179.28M | $169.55M | +12.3% |
| Operating income | $24.90M | -$33.65M | -$44.01M | -$81.94M | +174.0% |
| Net interest income | -$24.34M | -$25.16M | -$21.86M | -$11.52M | +3.3% |
| Pre-tax income | $554.00K | -$57.10M | -$63.50M | -$96.08M | +101.0% |
| Tax provision | $0 | -$2.27M | -$1.25M | -$1.42M | +100.0% |
| Net income | $554.00K | -$54.84M | -$62.26M | -$94.66M | +101.0% |
| Net income to common | $554.00K | -$54.84M | -$62.26M | -$94.66M | +101.0% |
| Basic EPS | 0.00 | -0.37 | -0.45 | -0.70 | +100.0% |
| Diluted EPS | 0.00 | -0.37 | -0.45 | -0.70 | +100.0% |
| EBIT | $29.64M | -$26.62M | -$36.90M | -$81.98M | +211.3% |
| EBITDA | $42.33M | -$13.99M | -$23.73M | -$69.31M | +402.5% |
| Basic shares | 160.43M | 146.77M | 137.67M | 135.63M | +9.3% |
| Diluted shares | 172.74M | 146.77M | 137.67M | 135.63M | +17.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $111.04M | $71.62M | $67.45M | $121.97M | +55.0% |
| Cash & short-term investments | $111.04M | $71.62M | $72.45M | $121.97M | +55.0% |
| Accounts receivable | $51.05M | $40.41M | $39.20M | $30.83M | +26.3% |
| Inventory | $68.67M | $48.17M | $38.84M | $24.73M | +42.5% |
| Total current assets | $240.31M | $167.66M | $156.26M | $186.82M | +43.3% |
| Property, plant & equipment | $27.06M | $28.21M | $29.18M | $9.51M | -4.1% |
| Goodwill & intangibles | $110.94M | $121.78M | $132.62M | $143.47M | -8.9% |
| Total assets | $383.53M | $323.06M | $322.60M | $344.52M | +18.7% |
| Total current liabilities | $109.57M | $100.44M | $95.19M | $73.62M | +9.1% |
| Current debt | — | $15.10M | — | — | — |
| Long-term debt | $220.34M | $217.01M | $190.93M | $187.07M | +1.5% |
| Total debt | $258.10M | $271.45M | $229.19M | $198.06M | -4.9% |
| Total liabilities | $369.84M | $352.68M | $329.38M | $299.33M | +4.9% |
| Retained earnings | -$671.31M | -$671.86M | -$617.02M | -$554.77M | +0.1% |
| Shareholder equity | $13.69M | -$29.61M | -$6.78M | $45.19M | +146.2% |
| Working capital | $130.74M | $67.22M | $61.07M | $113.20M | +94.5% |
| Net tangible assets | -$97.25M | -$151.40M | -$139.41M | -$98.28M | +35.8% |
| Shares issued | 166.22M | 149.43M | 138.13M | 136.27M | +11.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $554.00K | -$54.84M | -$62.26M | -$94.66M | +101.0% |
| Depreciation & amortisation | $12.69M | $12.63M | $13.16M | $12.67M | +0.5% |
| Stock-based compensation | $22.37M | $18.36M | $10.72M | $12.16M | +21.8% |
| Change in working capital | -$10.36M | -$8.82M | -$6.29M | -$35.15M | -17.5% |
| Operating cash flow | $28.63M | -$36.98M | -$47.02M | -$102.89M | +177.4% |
| Capital expenditure | -$696.00K | -$868.00K | -$2.26M | -$524.00K | +19.8% |
| Investing cash flow | -$696.00K | $4.88M | -$6.00M | $34.46M | -114.3% |
| Share buybacks | -$10.88M | -$3.73M | -$1.01M | -$468.00K | -191.3% |
| Financing cash flow | $11.39M | $36.17M | -$1.61M | $127.47M | -68.5% |
| Free cash flow | $27.93M | -$37.85M | -$49.29M | -$103.42M | +173.8% |
| End cash position | $115.06M | $75.74M | $71.67M | $126.31M | +51.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $92.10M | $83.13M | $85.81M | $74.38M | $71.54M | +10.8% |
| Operating revenue | $92.10M | $83.13M | $85.81M | $74.38M | $71.54M | +10.8% |
| Cost of revenue | $12.51M | $10.57M | $10.95M | $11.00M | $11.90M | +18.3% |
| Gross profit | $79.59M | $72.55M | $74.86M | $63.38M | $59.64M | +9.7% |
| Research & development | $10.67M | $8.78M | $7.87M | $7.48M | $8.05M | +21.5% |
| Selling, general & admin | $61.03M | $53.14M | $47.50M | $46.46M | $44.39M | +14.8% |
| Total operating expense | $74.42M | $64.64M | $58.09M | $56.65M | $55.16M | +15.1% |
| Operating income | $5.17M | $7.92M | $16.77M | $6.73M | $4.48M | -34.7% |
| Net interest income | -$5.49M | -$5.68M | -$5.69M | -$6.11M | -$6.41M | +3.3% |
| Pre-tax income | -$31.10M | $2.23M | $11.08M | $621.00K | -$1.93M | -1,492.2% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$31.10M | $2.23M | $11.08M | $621.00K | -$1.93M | -1,492.2% |
| Net income to common | -$31.10M | $2.23M | $11.08M | $621.00K | -$1.93M | -1,492.2% |
| Basic EPS | -0.18 | 0.01 | 0.07 | 0.00 | -0.01 | -1,900.0% |
| Diluted EPS | -0.18 | 0.01 | 0.06 | 0.00 | -0.01 | -1,900.0% |
| EBIT | -$24.15M | $9.12M | $18.23M | $7.89M | $5.43M | -364.9% |
| EBITDA | -$20.94M | $12.33M | $21.43M | $11.08M | $8.59M | -269.9% |
| Basic shares | 172.82M | 170.52M | 165.96M | 163.65M | 159.46M | +1.3% |
| Diluted shares | 172.82M | 177.63M | 180.07M | 177.62M | 159.46M | -2.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $121.75M | $111.75M | $111.04M | $91.60M | $59.28M | — | +8.9% |
| Cash & short-term investments | $121.75M | $111.75M | $111.04M | $91.60M | $59.28M | — | +8.9% |
| Accounts receivable | $58.10M | $56.30M | $51.05M | $53.75M | $53.05M | — | +3.2% |
| Inventory | $80.93M | $74.23M | $68.67M | $67.46M | $67.28M | — | +9.0% |
| Total current assets | $274.76M | $251.68M | $240.31M | $224.02M | $185.58M | — | +9.2% |
| Property, plant & equipment | $26.61M | $26.98M | $27.06M | $27.21M | $27.69M | — | -1.4% |
| Goodwill & intangibles | $105.52M | $108.23M | $110.94M | $113.65M | $116.36M | — | -2.5% |
| Total assets | $411.90M | $392.01M | $383.53M | $370.19M | $334.69M | — | +5.1% |
| Total current liabilities | $189.57M | $118.59M | $109.57M | $116.20M | $95.17M | — | +59.8% |
| Current debt | $63.78M | — | — | — | — | $11.96M | — |
| Long-term debt | $188.81M | $221.22M | $220.34M | $219.47M | $218.63M | — | -14.7% |
| Total debt | $289.44M | $258.55M | $258.10M | $257.65M | $257.22M | — | +11.9% |
| Total liabilities | $421.64M | $379.00M | $369.84M | $371.05M | $353.99M | — | +11.2% |
| Retained earnings | -$700.17M | -$669.07M | -$671.31M | -$682.39M | -$683.01M | — | -4.6% |
| Shareholder equity | -$9.73M | $13.01M | $13.69M | -$861.00K | -$19.30M | — | -174.8% |
| Working capital | $85.19M | $133.09M | $130.74M | $107.82M | $90.41M | — | -36.0% |
| Net tangible assets | -$115.25M | -$95.22M | -$97.25M | -$114.51M | -$135.66M | — | -21.0% |
| Shares issued | 173.59M | 172.56M | 166.22M | 165.53M | 161.22M | — | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$31.10M | $2.23M | $11.08M | $621.00K | -$1.93M | -1,492.2% |
| Depreciation & amortisation | $3.21M | $3.21M | $3.20M | $3.19M | $3.16M | 0.0% |
| Stock-based compensation | $11.07M | $4.14M | $5.27M | $7.64M | $5.01M | +167.3% |
| Change in working capital | -$6.60M | -$603.00K | -$373.00K | $6.14M | -$6.88M | -994.7% |
| Operating cash flow | $8.26M | $9.87M | $20.04M | $18.43M | $182.00K | -16.3% |
| Capital expenditure | -$209.00K | -$325.00K | -$333.00K | -$71.00K | -$279.00K | +35.7% |
| Investing cash flow | -$209.00K | -$325.00K | -$333.00K | -$71.00K | -$279.00K | +35.7% |
| Share buybacks | -$191.00K | -$17.02M | -$1.54M | -$478.00K | -$860.00K | +98.9% |
| Financing cash flow | $1.94M | -$8.84M | -$266.00K | $13.85M | $942.00K | +122.0% |
| Free cash flow | $8.05M | $9.54M | $19.71M | $18.36M | -$97.00K | -15.6% |
| End cash position | $125.77M | $115.77M | $115.06M | $95.62M | $63.41M | +8.6% |
Options analytics
Put / call volume
0.07
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-75.2% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+1.6%
Puts bid over calls
Call volume
297
Contracts, this expiry
Put volume
20
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.00 | -0.00 | -172.0% |
| Mar 2026 | -0.00 | 0.01 | +1,592.5% |
| Dec 2025 | 0.05 | 0.06 | +33.3% |
| Sep 2025 | 0.00 | 0.00 | -100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.03 | 3 | $101.68M | +36.7% |
| Next quarter | 0.05 | 2 | $111.02M | +29.4% |
| Current year | -0.02 | 3 | $387.90M | +32.9% |
| Next year | 0.37 | 3 | $480.03M | +23.8% |
Analyst targets & ownership
Mean target$12.86
High target$18.00
Low target$8.00
Implied upside29.22%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold1
Sell / Strong sell0 / 0
Held by insiders3.03%
Held by institutions60.15%
Institutions holding312
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.46
+5.17% from price
SMA 20
8.71
+15.63% from price
SMA 50
8.53
+18.04% from price
SMA 100
7.91
+25.83% from price
SMA 200
7.23
+39.33% from price
EMA 12
9.35
+6.46% from price
EMA 26
8.93
+11.39% from price
EMA 50
8.58
+15.91% from price
RSI (14)
66.1
Neutral
MACD (12,26,9)
0.41
Hist 0.14
ATR (14)
0.64
6.41% of price
Realised vol 30D
59.5%
Annualised
Bollinger upper
10.50
20, 2σ
Bollinger lower
6.92
20, 2σ
50 / 200 cross
Golden
8.53 vs 7.23
Trend bias
Above 200
+39.33%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.84
Less volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
59.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-46.6%
Peak to trough
Max drawdown 5Y
-64.8%
Peak to trough
ATR 14
0.64
6.41% of price
Beta (reported)
0.84
5Y monthly, from filing
Short interest
Shares short
8.06M
Prior 8.73M
Change vs prior
-7.7%
Shorts covering
% of float
4.57%
Normal
% of shares out
4.42%
Against total outstanding
Days to cover
5.1
Crowded exit
Float
176.07M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 10, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Aug 20, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Mar 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 9, 25 | Barclays | INITIATED | — | Overweight |
| Nov 7, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Nov 7, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 7, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Oct 29, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Sep 17, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 19, 25 | Leerink Partners | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-09
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-17
Corporate Changes & Voting Matters
8-K · 2026-06-30
Corporate Changes & Voting Matters
8-K · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-06-05
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-23
Headlines
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire · 5d ago
Update: Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
MT Newswires · 7d ago
Xeris Biopharma Holdings Insider Sold Shares Worth $250,000, According to a Recent SEC Filing
MT Newswires · 8d ago
Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports
Investing.com · 8d ago
Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’
Stocktwits · 8d ago
Sector Update: Healthcare Stocks Decline Tuesday Afternoon
MT Newswires · 8d ago
Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
MT Newswires · 8d ago
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Business Wire · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.